Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial.

What Was Tested

The paper reports a study of Elafin, published as a randomized controlled trial.

Tiprelestat (recombinant human elafin) reversibly inhibits human neutrophil elastase.

This protein had yet not been tested in COVID-19 patients.

Who Took Part

The abstract describes 19 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

This prospective, multicenter, randomized, double-blind, placebo-controlled trial investigated Tiprelestat in adult patients hospitalized for COVID-19 in 7 hospitals in Germany between May 2023 and May 2024.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Elafin and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Elafin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Elafin group a baseline to be compared against.

Running at several centres spread the Elafin study over different clinics and patient groups.

What Was Measured

This protein had yet not been tested in COVID-19 patients.

The subject headings attached to it are COVID-19 Drug Treatment, COVID-19, Hospitalization, SARS-CoV-2, Leukocyte Elastase and Germany.

The authors tagged it with the keywords Drug safety, Neutrophil elastase, Recombinant human elafin, Tiprelestat and Tissue injury during inflammation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Elafin in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Advances in therapy), a journal based in United States.

More context: the Elafin compound page, all human trials.